- COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.
- Clinical data for AxoGen's key Avance product remain quite strong, showing equal-to-better efficacy compared to allografts and superiority to manufactured conduits.
- Results from RECON could help the sales effort, but that's at least two years from now, and AxoGen must grow its business beyond its core high-use base.
- AxoGen isn't the first small-cap med-tech to struggle commercializing a disruptive technology; the shares still look undervalued, but execution risk is very high.
For further details see:
AxoGen Struggling Through A Protracted Restructuring